Overview

• UK medical device firm's revenue grew 17% to £48.7 mln, exceeding market expectations

• Adjusted EBITDA rose 21% to £16.7 mln, beating consensus expectations

• Company launched new NIOX PRO® device with first sale in December 2025

Outlook

• Company expects future research sales to align with historical levels

• Niox aims to drive further adoption of FeNO testing worldwide

• Company sees strong commercial momentum entering 2026

Result Drivers

• RESEARCH SALES - Research revenue grew 77% due to increased clinical trial activity involving FeNO testing for asthma and COPD

• NIOX PRO® LAUNCH - Successful introduction of next-generation NIOX PRO® device with first sale in December 2025

• DIRECT SALES MODEL - Transition to direct US sales model expected to support stronger growth in Clinical business

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Niox Group PLC is GBP83.00, about 20.6% above its January 19 closing price of GBP68.80

• The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 23 three months ago

Press Release: ID:nRST5034Pa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)